Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
AZD5851 for Liver Cancer
Recruiting1 awardPhase 1 & 2
San Francisco, California
This trial is testing AZD5851, a new drug, in adults with advanced liver cancer that has a specific marker (GPC3) and hasn't responded to other treatments. The drug aims to target and kill these specific cancer cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service